Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamadermatol.2013.6759 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Controlling Prescribing through "Preferred Drug" Targets-The Bavarian Experience.
Int J Environ Res Public Health
September 2024
Institute of General Practice/Family Medicine, Philipps University of Marburg, Karl-von-Frisch-Straße 4, 35043 Marburg, Germany.
Article Synopsis
- The Bavarian Drug Agreement aims to manage rising drug costs by setting prescribing targets for preferred and generic medications, with healthcare providers receiving feedback and facing potential penalties based on their performance.
- Analysis of prescribing data from early 2018 showed that while high-volume drug targets are generally met, many less common targets are often missed, particularly in pediatric care.
- Generic drugs tend to be prescribed more effectively than recommended medications, as prescribers struggle with new, expensive options that may provide unclear benefits, leading to challenges in meeting targets.
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data.
Eur J Cancer
September 2023
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy. Electronic address:
Background: Phase I clinical trials have become increasingly critical to regulatory approvals of novel agents. In phase I drug development, a global problem of unknown magnitude is the multiplicity of similar drugs being investigated against the same target, colloquially known as the 'me too' phenomenon.
Methods: Ranging from December 2020 to December 2022 we annotated phase I clinical trials present on clinicaltrials.
Characterization and exploration of an artifact in the reducing capillary electrophoresis-sodium dodecyl sulfate analysis of the 'me-too' drug zuberitamab related to rituximab.
J Pharm Biomed Anal
May 2023
Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310016, China; Innovation Center of Translational Pharmacy, Jinhua Institute of Zhejiang University, Jinhua 321000, China; Research Institute of Zhejiang University-Taizhou, Taizhou 317000, China. Electronic address:
For monoclonal antibody (mAb) drugs, the 'me-too' drug is a pharmacologically active compound that is structurally similar to the first-in-class drugs, acting on the same target and is used for the same therapeutic purposes, but it may differ in drug-drug interactions and adverse drug reactions. Capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) has been widely used for quality evaluation of mAb drugs. The properties of the detected substances can interfere with the credibility and accuracy of the method.
View Article and Find Full Text PDFThe Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy.
ACS Pharmacol Transl Sci
February 2023
Organic Chemistry, Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Jerusalem 9190401, Israel.
Drug repurposing toward new medical uses and chiral switches are elements of secondary pharmaceuticals. The drug repurposing and chiral-switches strategies have mostly been applied independently in drug discovery. Drug repurposing has peaked in the search for therapeutic treatments of the Coronavirus Disease 2019 pandemic, whereas chiral switches have been overlooked.
View Article and Find Full Text PDFSeventy Years of Antipsychotic Development: A Critical Review.
Biomedicines
January 2023
UNLV School of Medicine, University of Nevada, Las Vegas, NV 89154, USA.
Since the mid-1950s discovery of the first effective antipsychotic medications (APM), we have only been able to improve the tolerability but not the overall efficacy of currently available APMs, as reflected by effectiveness trials in Europe and the United States. This inability to develop more effective APMs is attributable to multiple factors, including failure to create and use assessment tools to assess core symptom domains in schizophrenia, move beyond the dopaminergic hypothesis and to develop "me too" drugs, imposing ill-defined research domain criteria, and lacking federal funding for clinical trials. The classification of APMs is also confusing, including second-generation, partial agonists, and multimodal APMs in the same class of APMs, despite significant differences in their mechanisms of action.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!